Key result
In patients with systemic sclerosis and ventricular arrhythmias, an implantable cardioverter defibrillator successfully reverted malignant ventricular tachycardia in 3 of 10 patients over 36 months.
Why the study?
Does an implantable cardioverter defibrillator prevent sudden cardiac death in patients with systemic sclerosis and ventricular arrhythmias?
Observational (n=10)
No
Does an implantable cardioverter defibrillator prevent sudden cardiac death in patients with systemic sclerosis and ventricular arrhythmias?
ICD implantation in systemic sclerosis patients with malignant ventricular arrhythmias effectively terminates life-threatening arrhythmias, potentially preventing sudden cardiac death.
Answers are grounded in this paper and cite their sources.
May support ICD evaluation in systemic sclerosis with ventricular arrhythmias; hypothesis-generating without randomized data.
OBJECTIVE: Cardiac involvement means a poor prognosis in systemic sclerosis (SSc). Conduction defects and arrhythmias are frequent in patients with SSc, and may result in sudden cardiac death. We tested whether electrophysiologic studies and implantation of cardioverter defibrillators are recommended when ventricular arrhythmias are present. METHOD: A cardioverter defibrillator was implanted in 10 patients with SSc who had heart involvement. RESULT: After 36 months, analysis of the device showed several episodes of ventricular tachycardia in 3 patients, which were promptly reverted by electrical shock delivery. CONCLUSION: In patients with SSc who are affected by ventricular arrhythmias, the implantation of a cardioverter defibrillator may prevent sudden cardiac death.
No takes yet. Share an insight, caveat, or question.
Bernardo et al. (2011) conducted an observational in Systemic Sclerosis with ventricular arrhythmias (n=10). Implantable Cardioverter Defibrillator (ICD) was evaluated on Episodes of ventricular tachycardia reverted by electrical shock. In patients with systemic sclerosis and ventricular arrhythmias, an implantable cardioverter defibrillator successfully reverted malignant ventricular tachycardia in 3 of 10 patients over 36 months.
Synapse has enriched 10 related papers. Consider them for comparative context: